CN101668750A - 4-苯胺喹唑啉衍生物的盐 - Google Patents

4-苯胺喹唑啉衍生物的盐 Download PDF

Info

Publication number
CN101668750A
CN101668750A CN200880005090A CN200880005090A CN101668750A CN 101668750 A CN101668750 A CN 101668750A CN 200880005090 A CN200880005090 A CN 200880005090A CN 200880005090 A CN200880005090 A CN 200880005090A CN 101668750 A CN101668750 A CN 101668750A
Authority
CN
China
Prior art keywords
salt
acid
addition salts
cancer
quinazoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880005090A
Other languages
English (en)
Inventor
郭建辉
姜勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Allist Pharmaceuticals Inc
Original Assignee
Shanghai Allist Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Allist Pharmaceuticals Inc filed Critical Shanghai Allist Pharmaceuticals Inc
Priority to CN201510098689.0A priority Critical patent/CN104628658B/zh
Priority to CN200880005090A priority patent/CN101668750A/zh
Publication of CN101668750A publication Critical patent/CN101668750A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明提供N－{4－[3－氯－4－(3－氟－苄氧基)苯基胺基]－喹唑啉－6－基}－丙烯酰胺的成盐形式、其制备方法、包含该成盐形式的药物组合物及该成盐形式的应用。本发明的盐具有优异肿瘤抑制活性，且在动物体内的生物利用度良好、毒性低，适于制备抗肿瘤用的制剂。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN200880005090A 2007-02-14 2008-02-04 4-苯胺喹唑啉衍生物的盐 Pending CN101668750A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201510098689.0A CN104628658B (zh) 2007-02-14 2008-02-04 4-苯胺喹唑啉衍生物的盐
CN200880005090A CN101668750A (zh) 2007-02-14 2008-02-04 4-苯胺喹唑啉衍生物的盐

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNA2007100375572A CN101245050A (zh) 2007-02-14 2007-02-14 4-苯胺喹唑啉衍生物的盐
CN200710037557.2 2007-02-14
CN200880005090A CN101668750A (zh) 2007-02-14 2008-02-04 4-苯胺喹唑啉衍生物的盐

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510098689.0A Division CN104628658B (zh) 2007-02-14 2008-02-04 4-苯胺喹唑啉衍生物的盐

Publications (1)

Publication Number Publication Date
CN101668750A true CN101668750A (zh) 2010-03-10

Family

ID=39689656

Family Applications (3)

Application Number Title Priority Date Filing Date
CNA2007100375572A Pending CN101245050A (zh) 2007-02-14 2007-02-14 4-苯胺喹唑啉衍生物的盐
CN200880005090A Pending CN101668750A (zh) 2007-02-14 2008-02-04 4-苯胺喹唑啉衍生物的盐
CN201510098689.0A Active CN104628658B (zh) 2007-02-14 2008-02-04 4-苯胺喹唑啉衍生物的盐

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNA2007100375572A Pending CN101245050A (zh) 2007-02-14 2007-02-14 4-苯胺喹唑啉衍生物的盐

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510098689.0A Active CN104628658B (zh) 2007-02-14 2008-02-04 4-苯胺喹唑啉衍生物的盐

Country Status (8)

Country Link
US (1) US8349854B2 (zh)
EP (1) EP2116540B1 (zh)
JP (1) JP5504460B2 (zh)
KR (1) KR20100014947A (zh)
CN (3) CN101245050A (zh)
AU (1) AU2008215053B2 (zh)
CA (1) CA2677978C (zh)
WO (1) WO2008098485A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101347433B (zh) * 2007-07-20 2012-05-02 江苏艾力斯生物医药有限公司 4-苯胺喹唑啉衍生物的制药用途
CN101544609A (zh) * 2008-03-25 2009-09-30 上海艾力斯医药科技有限公司 4-苯胺喹唑啉衍生物的结晶形式
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
TWI740873B (zh) 2015-12-24 2021-10-01 日商協和麒麟股份有限公司 α、β不飽和醯胺化合物
CN106117182B (zh) * 2016-06-20 2019-08-30 中国药科大学 喹唑啉-n-苯乙基四氢异喹啉类化合物及其制备方法和应用
CN112225679A (zh) * 2020-10-13 2021-01-15 苏州亚科科技股份有限公司 一种3-(环己胺)-2-羟基-1-丙磺酸的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
EP0817775B1 (en) 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
DK0892789T4 (da) 1996-04-12 2010-04-06 Warner Lambert Co Irreversible inhibitorer af tyrosin kinaser
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
AR020114A1 (es) 1998-07-30 2002-04-10 America Home Products Corp Proceso para la preparacion de derivados de quinazolina sustituida y compuestos para su exclusivo uso en dicho proceso
TW200914443A (en) * 2000-06-30 2009-04-01 Glaxo Group Ltd Process for preparing substituted quinazolinyl furanaldehyde
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
CN101003514A (zh) * 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途

Also Published As

Publication number Publication date
CA2677978C (en) 2015-04-07
JP5504460B2 (ja) 2014-05-28
EP2116540A1 (en) 2009-11-11
AU2008215053A1 (en) 2008-08-21
CN104628658A (zh) 2015-05-20
CN101245050A (zh) 2008-08-20
KR20100014947A (ko) 2010-02-11
US8349854B2 (en) 2013-01-08
WO2008098485A1 (fr) 2008-08-21
EP2116540B1 (en) 2014-08-13
AU2008215053B2 (en) 2013-10-24
EP2116540A4 (en) 2010-04-28
US20100168142A1 (en) 2010-07-01
CN104628658B (zh) 2015-10-21
CA2677978A1 (en) 2008-08-21
JP2010518173A (ja) 2010-05-27

Similar Documents

Publication Publication Date Title
CN101103005B (zh) 喹唑啉衍生物、其制备方法及用途
US9102629B2 (en) Polymorphic forms of 4-phenylamine quinazoline derivative, the preparation method and uses thereof
CN101668750A (zh) 4-苯胺喹唑啉衍生物的盐
WO2016023217A1 (zh) 喹唑啉衍生物、其制备方法、药物组合物和应用
CN111303123B (zh) 2-(2,4,5-取代苯胺基)嘧啶化合物及其应用
CN113773305B (zh) 一种氨基嘧啶衍生物及其作为egfr酪氨酸激酶抑制剂的应用
CN103864680B (zh) 具有抗肿瘤活性的氯氧喹衍生物
CN109988110A (zh) 4-苯氧基喹啉并磺酰脲类化合物、合成该化合物的中间体及其制备方法和用途
WO2018036539A1 (zh) 喹唑啉衍生物的盐的晶体
CN101932326A (zh) 4-苯胺喹唑啉衍生物的制药用途
WO2016127949A1 (zh) 作为t790变异抑制剂的嘧啶衍生物
CN105294578A (zh) 具有靶向抗肿瘤活性的喹唑啉衍生物
CN115785107A (zh) 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100310